Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 254, 93-101
Abstract
No abstract availableKeywords
Funding Information
- Deanship of Scientific Research at the University of Jordan (Grant No. 1461)
This publication has 31 references indexed in Scilit:
- Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysisEuropean Journal of Medicinal Chemistry, 2014
- Adenosine A2A receptor antagonists in Parkinson's disease: still in the runningThe Lancet Neurology, 2014
- Elaborate Ligand-Based Modeling Coupled with Multiple Linear Regression and k Nearest Neighbor QSAR Analyses Unveiled New Nanomolar mTOR InhibitorsJournal of Chemical Information and Modeling, 2013
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)Annals of Neurology, 2008
- 2-Amino-N-pyrimidin-4-ylacetamides as A2AReceptor Antagonists: 2. Reduction of hERG Activity, Observed Species Selectivity, and Structure−Activity RelationshipsJournal of Medicinal Chemistry, 2008
- 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liabilityBioorganic & Medicinal Chemistry Letters, 2008
- Adenosine A2A receptors and basal ganglia physiologyProgress in Neurobiology, 2007
- Adenosine receptor–dopamine receptor interactions in the basal ganglia and their relevance for brain functionPhysiology & Behavior, 2007
- Adenosine receptors: G protein-mediated signalling and the role of accessory proteinsCellular Signalling, 2002